Update shared on23 Sep 2025
Fair value Decreased 3.00%Analyst sentiment on Ypsomed Holding has turned more cautious, citing diverging views on the sustainability of recent growth and transformation despite ongoing demand in injectables, resulting in a lowered consensus price target from CHF463.26 to CHF449.37.
Analyst Commentary
- Bullish analysts highlight Ypsomed's leading position in the high-growth injectable market.
- The company has completed a successful transformation from a diabetes conglomerate to a pure-play injectables company after four divestitures.
- Bullish analysts cite unprecedented demand in the injectables market as a growth catalyst.
- Bearish analysts remain cautious, reinstating coverage with an underperform rating and a lower price target.
- Diverging views among analysts reflect differing opinions on the sustainability of Ypsomed's recent growth and transformation.
Valuation Changes
Summary of Valuation Changes for Ypsomed Holding
- The Consensus Analyst Price Target has fallen slightly from CHF463.26 to CHF449.37.
- The Consensus Revenue Growth forecasts for Ypsomed Holding has fallen from 6.7% per annum to 6.1% per annum.
- The Net Profit Margin for Ypsomed Holding has fallen slightly from 27.08% to 26.35%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.